Alingasa, Relmar C.
HRN: 22-64-33 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
02/24/2023
NYSTATIN 100,000IU/ML, 30ML SUSPENSION (BOT)
02/24/2023
03/03/2023
ORAL
400,000 U
Q6hrs
Oral Candidiasis
Waiting Final Action
Indication: Empiric Type of Infection: Urinary Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes